Showing results (21-30 of 51) with videos related to
Sort By:
Pageof 6
Journal of Pharmacokinetics and Pharmacodynamics|November 15, 2005
A longitudinal model for non-monotonic clinical assessment scale dataFredrik Jonsson, Scott Marshall, Michael Krams, et al.Journal of Biopharmaceutical Statistics|January 19, 2012
A bayesian dose-finding design adapting to efficacy and tolerability responseS Krishna Padmanabhan, Scott Berry, Vladimir Dragalin, et al.Pharmaceutical Statistics|November 4, 2006
Implementation of a Bayesian adaptive design in a proof of concept studyMichael K Smith, Ieuan Jones, Mark F Morris, et al.Stroke|June 14, 2003
UK-279,276, a neutrophil inhibitory glycoprotein, in acute stroke: tolerability and pharmacokineticsKennedy R Lees, Hans-Christoph Diener, Kjell Asplund, et al.Clinical Pharmacokinetics|February 21, 2006
Role of mechanistically-based pharmacokinetic/pharmacodynamic models in drug development : a case study of a therapeutic proteinScott Marshall, Fiona Macintyre, Ian James, et al.Behavioural Brain Research|June 23, 2005
Assessing combination treatments in acute stroke: preclinical experiencesMei Lu, Michael Krams, Li Zhang, et al.Pharmaceutical Research|August 4, 2005
Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated dispositionE Niclas Jonsson, Fiona Macintyre, Ian James, et al.Pharmaceutical Statistics|December 9, 2015
Continuous event monitoring via a Bayesian predictive approachJianing Di, Daniel Wang, H Robert Brashear, et al.Nature Reviews. Drug Discovery|September 1, 2012
Down's syndrome and Alzheimer's disease: towards secondary preventionSeth Ness, Michael Rafii, Paul Aisen, et al.Journal of Biopharmaceutical Statistics|May 27, 2006
Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working GroupPaul Gallo, Christy Chuang-Stein, Vladimir Dragalin, et al.Pageof 6